

CSD/BSE&NSE/2025-26

January 17, 2026

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001  
**Scrip Code: 543064**

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: COHANCE**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding grant of ESOPs**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”), we hereby inform that the Nomination and Remuneration Committee of the Board of Directors of the Company, on January 17, 2026, has approved grant of 3,89,668 stock options to the eligible employees of the Company under the Employee Stock Option Plan 2023 (“**ESOP 2023**”). This grant also includes 2,18,077 stock options granted pursuant to, and in accordance with, the Scheme of Amalgamation between erstwhile Cohance Lifesciences Limited as the transferor company (the “**Transferor Company**”) and the Company as the transferee company, approved by the Hon’ble National Company Law Tribunal (“**NCLT**”) vide order dated March 27, 2025 (“**Scheme of Amalgamation**”), which is available on the Company website at [https://www.cohance.com/wp-content/uploads/2025/06/Draft\\_Scheme-Cohance\\_with\\_Suven.pdf](https://www.cohance.com/wp-content/uploads/2025/06/Draft_Scheme-Cohance_with_Suven.pdf).

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 on the captioned subject is annexed herewith.

We request you to take this information on record.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above



**Grant of stock options**

Sl	Particulars	Details
a	Brief details of options granted	In aggregate 3,89,668 stock options have been granted to the eligible employees of the Company. This grant also includes 2,18,077 stock options granted pursuant to, and in accordance with, the Scheme of Amalgamation approved by the Hon'ble NCLT <i>vide</i> its order dated March 27, 2025, which options shall also be governed by the terms of ESOP 2023.
b	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes, the ESOP 2023 has been formulated in accordance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
c	Total number of shares covered by these options	3,89,668 equity shares of Re. 1 each of the Company. Each stock option carries the right to apply for and be allotted 1 (one) equity share of face value of Re. 1 each of the Company.
d	Pricing formula	As per ESOP 2023.
e	Options vested/ vesting period	1,71,591 options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 10 (ten) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, but subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees. Further, in terms of the Scheme of Amalgamation and ESOP 2023, with respect to the 2,18,077 stock options that are granted in lieu of the stock options held by the employees of the Transferor Company, the period during which such employees held the stock options in the Transferor Company shall be taken into account for determining the vesting period required under applicable laws and the ESOP 2023. The stock options of the Transferor Company were originally granted on March 14, 2023 and/or February 26, 2024. The 2,18,077 stock options granted to the employees of the Transferor Company pursuant to the Scheme of Amalgamation read with the ESOP 2023, shall vest on April 1, 2026.
f	Time within which option may be exercised	The exercise period shall be upto 3 (three) years from the date of vesting of Options.
g	Options exercised	Not applicable.
h	Money realized by exercise of options	Not applicable.
i	Total number of shares arising as a result of exercise of option	Not applicable.
j	Options lapsed	Not applicable.

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Corporate Office:** 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.  
Tel: +91 40 2354 9414 / 3311

**Regd. Office:** 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.  
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: [www.cohance.com](http://www.cohance.com) | Company Email: [reachus@cohance.com](mailto:reachus@cohance.com)



k	Variation of terms of options	Not applicable.
l	Brief details of significant terms	Significant terms of the stock options have been given in the Scheme, which can be accessed on the website of the Company.
m	Subsequent changes or cancellation or exercise of such options	Not applicable.
n	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not applicable.

---

**Cohance Lifesciences Limited**

(Formerly, Suven Pharmaceuticals Limited)

**Corporate Office:** 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.  
Tel: +91 40 2354 9414 / 3311

**Regd. Office:** 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharastra - 400093.  
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: [www.cohance.com](http://www.cohance.com) | Company Email: [reachus@cohance.com](mailto:reachus@cohance.com)

